182 related articles for article (PubMed ID: 9618417)
1. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
2. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
3. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
4. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
5. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
6. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
8. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.
Huang P; Liu-Chen LY; Unterwald EM; Cowan A
Neurosci Lett; 2009 Nov; 465(1):66-70. PubMed ID: 19733208
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
10. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
11. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
12. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
Aceto MD; Scates SM; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
[TBL] [Abstract][Full Text] [Related]
13. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.
Valverde O; Maldonado R; Valjent E; Zimmer AM; Zimmer A
J Neurosci; 2000 Dec; 20(24):9284-9. PubMed ID: 11125007
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome.
Sañudo-Peña MC; Force M; Tsou K; McLemore G; Roberts L; Walker JM
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1121-4. PubMed ID: 11216447
[TBL] [Abstract][Full Text] [Related]
17. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.
Wilson DM; Varvel SA; Harloe JP; Martin BR; Lichtman AH
Pharmacol Biochem Behav; 2006 Sep; 85(1):105-13. PubMed ID: 16934319
[TBL] [Abstract][Full Text] [Related]
18. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.
Balerio GN; Aso E; Berrendero F; Murtra P; Maldonado R
Eur J Neurosci; 2004 Nov; 20(10):2737-48. PubMed ID: 15548217
[TBL] [Abstract][Full Text] [Related]
19. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
20. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
